Expression of CDK7, cyclin H and MAT1 is elevated in breast cancer and is prognostic in estrogen receptor positive breast cancer

Hetal Patel[1], Rezvan Abduljabbar[2], Chun-Fui Lai[1], Manikandan Periyasamy[1], Alison Harrod[1], Carolina Gemma[1], Jennifer H. Steel[1], Naina Patel[1], Claudia Busonero[1], Dena Jerjees[2], Judit Remenyi[3], Sally Smith[4], Jennifer J. Gomm[4], Luca Magnani[1], Balázs Győrffy[5, 6], Louise J. Jones[4], Frances Fuller-Pace[3], Sami Shousha[7], Laki Buluwela[1], Emad A. Rakha[2], Ian O. Ellis[2], R. Charles Coombes[1], Simak Ali[1,*]

[1]Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK

[2]Department of Cancer and Stem Cells, School of Medicine, University of Nottingham, Nottingham, UK

[3]Division of Cancer Research, University of Dundee, Ninewells Hospital & Medical School, Dundee, UK

[4]Centre for Tumour Biology, Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London EC1M 6BQ, UK

[5]MTA TTK Lendület Cancer Biomarker Research Group, Budapest, Hungary

[6]Semmelweis University 2nd Dept. of Pediatrics, Budapest, Hungary

[7]Department of Histopathology, Charing Cross Hospital, Imperial College London W6 8RF, UK

[*]Author for correspondence: Simak Ali, Department of Surgery & Cancer, Imperial College London, Du Cane Road, London W12 0NN, UK

Email: simak.ali@imperial.ac.uk

Running title: CDK7 expression in breast cancer

Statement of translational relevance

Cyclin-dependent kinase 7 (CDK7) is a critical regulator of cell cycle progression and gene expression, processes that are frequently deregulated in cancer. As such, inhibition of CDK7 activity has been proposed as a therapeutic strategy for the treatment of cancer, an aim that is supported by the recent development of selective CDK7 inhibitors with potent anti-cancer activities. Since CDK7 is centrally involved in key cellular processes in all cells, the use of CDK7 inhibitors could be limited by a toxicity associated with its function in normal tissues. Using mRNA expression profiling and immunohistochemistry, we find that expression of CDK7, as well as the associated co-factors CyclinH and MAT1, are all elevated in breast cancer, suggesting that this tumour type may be especially sensitive to CDK7 inhibition and that the CDK7 over-expression may allow mitigation of any toxicity seen in normal tissues.

ABSTRACT

Purpose: CDK-activation kinase (CAK) is required for the regulation of the cell-cycle and is a trimeric complex consisting of Cyclin Dependent Kinase 7 (CDK7), Cyclin H and the accessory protein, MAT1. CDK7 also plays a critical role in regulating transcription, primarily by phosphorylating RNA polymerase II, as well as transcription factors such as estrogen receptor-α (ER). Deregulation of cell cycle and transcriptional control are general features of tumor cells, highlighting the potential for the use of CDK7 inhibitors as novel cancer therapeutics.

Experimental Design: mRNA and protein expression of CDK7 and its essential co-factors cyclinH and MAT1, were evaluated in breast cancer samples to determine if their levels are altered in cancer. Immunohistochemical staining of >900 breast cancers was used to determine the association with clinicopathological features and patient outcome.

Results: We show that expression of CDK7, cyclinH and MAT1 are all closely linked at the mRNA and protein level and their expression is elevated in breast cancer compared with the normal breast tissue. Intriguingly, CDK7 expression was inversely proportional to tumour grade and size and outcome analysis showed an association between CAK levels and better outcome. Moreover, CDK7 expression was positively associated with ER expression and in particular with phosphorylation of ER at serine 118, a site important for ER transcriptional activity.

Conclusions: Expression of components of the CAK complex, CDK7, MAT1 and Cyclin H are elevated in breast cancer and correlates with ER. Like ERα, CDK7 expression is inversely proportional to poor prognostic factors and survival.

INTRODUCTION

Cyclin dependent kinases (CDKs) control cell proliferation by regulating entry into and passage through the cell cycle (1). The appropriate action of cell cycle CDKs is ensured by regulation of their activities through the availability of partner cyclins, interaction with CDK inhibitors (CDKi) and through their phosphorylation. Phosphorylation at a key threonine residue in the activation (T) loop facilitates and/or stabilizes the CDK-cyclin complex (2). In metazoans, T-loop phosphorylation is mediated by the CDK-activation kinase (CAK), a trimeric complex consisting of CDK7, CyclinH and the accessory protein, MAT1. Importantly, CDK7 is also required for transcription by phosphorylating the C-terminal heptapeptide repeat domain (CTD) of RNA Polymerase II (PolII), a step that is required for gene promoter release and transcription initiation by PolII. Importantly, CDK7 also modulates regulated gene expression by phosphorylating transcription factors, including p53 (3), retinoid receptors (4, 5), androgen receptor (6, 7) and ER (8). Ligand-dependent phosphorylation of serine 118 (Ser118), important for ERα function and turnover, is mediated by CDK7 (8).

Deregulation of CDK activity by multiple mechanisms, for example, cyclin upregulation and mutation, silencing or loss of genes encoding CDK inhibitors or Rb, commonly feature in cancer (9, 10). Hence, the development of inhibitors of cell cycle CDKs for cancer treatment has received considerable attention and numerous small molecule inhibitors have been described (11). Surprisingly, genetic studies have indicated that cell cycle CDKs, with the exception of CDK1, are not essential for most cell types (12, 13). Nevertheless, following an initial disappointment with several candidate drugs, newer CDK-selective inhibitors have offered renewed optimism in the utility of these targets. In particular, CDK4/6 selective inhibitors have shown promise against a broad range of cancers, including breast cancer, but can be ineffective, for example where Rb is absent or inactivated (14, 15). Additionally, CDK4/6 inhibitors are efficacious in combination with hormone therapies, for the treatment of ERα-positive advanced breast cancer (16).

Transcription inhibition appears to be important for the anti-tumour activities of several broad range CDK inhibitors, such as flavopiridol and seliciclib, which inhibit CDK7 and CDK9 (phosphorylation of PolII by CDK9 is needed for transcription elongation), in addition to inhibiting other CDKs. The action of these drugs has been linked to a reduction in PolII phosphorylation and reduced expression of short-lived anti-apoptotic proteins such as Mcl-1 and XIAP, to promote apoptosis (15). The dual role of CDK7 in transcription and the cell cycle means that CDK7 inhibitors potentially provide a potent means of blocking cell cycle progression, together with the promotion of apoptosis by transcription inhibition in cell lines from a variety of cancer types, including breast, leukaemia, neuroblastoma and lung (17-20). In the latter tumor types, the effects of CDK7 on RUNX1 and MYC expression and function are critical factors in the action of CDK7 inhibition. A further reason for CDK7 as a cancer target is that, although required for early embryonic development, CDK7 was not found to be essential in adult tissues with low proliferative indices (21), indicating that CDK7 selective inhibitors might not show general toxicity in cancer patients.

We have investigated the expression of CDK7 in breast cancer, since this might further support the case for the use of CDK7 selective inhibitors for cancer therapy, particularly in this tumour type. By profiling expression of the components of the CAK complex, CDK7, CyclinH, and MAT1 in the normal and malignant breast, we demonstrate that their expression is coordinately elevated in breast cancer, especially in ER-positive tumours, compared with normal breast tissue. We also show that CDK7, cyclinH and MAT1 expression is correlated with ER levels and is related to a good patient prognosis.

MATERIALS AND METHODS

Breast Cancer Samples

Tumour and surrounding normal tissue: Tissue samples (snap frozen) were obtained from patients undergoing breast surgery between 2011 and 2013; all patients gave their consent according to the tissue bank protocol (see below). Samples of tumour tissue and surrounding morphologically normal tissue, taken >5cm from the tumour, were obtained from each patient. All samples were obtained from the Barts Cancer Institute Breast Tissue Bank and were covered by Research Tissue Bank Ethics Approval. RNA was also prepared from tumours from 74 patients who presented with primary, operable breast cancer to the Dundee Cancer Centre between 1997 and 2012 and provided written, informed consent for research use of their tissues; the Tayside Tissue Bank under delegated authority from the Tayside Local Research Ethics Committee approved the use of the clinical material and data. ER immunohistochemical staining and scoring was carried out as described (22). TMAs were prepared from a series of primary operable breast cancer carcinoma cases from 1986-1999 aged 70 years or less at the Nottingham Breast Unit. Patient selection and treatment details have been reported previously (23, 24).

RNA preparation and quantitative RT-PCR (qRT-PCR)

50-100mg of frozen tissue was homogenised using TissueLyser (Qiagen, Germany) with stainless steel ball bearings (5mm) in 0.7 ml of lysis/binding buffer and the total RNA extracted using an RNeasy kit (Qiagen), according to the manufacturer's instructions. RNA purity and concentration was measured using a Nanodrop™ 1000 spectrophotometer (Nanodrop Technolodies, Wilmington, DE, USA). cDNA was prepared by reverse transcription of 2.0μg of total RNA, in a final volume of 20μl using RevertAid M-MuLV reverse transcriptase (Fermentas, York, UK) and random hexamer oligonucleotide priming. Quantitative gene expression analysis was carried out using real-time PCR and Taqman gene expression assays for CDK7 (Hs00361486_m1), CyclinH

(Hs00236923_m1), MAT1 (Hs01041574_m1) and GAPDH (Hs99999905_m1) (Life technologies). Gene expression was normalized to GAPDH expression using the $2^{-\Delta\Delta CT}$ method (25).

Gene expression and correlation analysis of microarray data

Expression of CDK7, CyclinH and MAT1 was analysed in normal breast (n=144) and breast cancer (n=1556) samples from the METABRIC dataset using Oncomine (26). For the expression of ER, CDK7, CyclinH, MAT1 and PGR in the METABRIC dataset of patient samples (n=1959), median expression was used as the cutoff in a Cox regression analysis. Kaplan-Meier survival plot, and hazard ratio with 95% confidence intervals, logrank p-value and correlation scores (Pearson and Spearman) were calculated and plotted in R using Bioconductor packages.

Immunohistochemistry

Mouse monoclonal antibodies for CDK7 (ab115181, Abcam) and cyclinH (ab54903, Abcam) and MAT1 (sc-135981, Santa Cruz Biotechnology) were used for immunohistochemistry (IHC) at a working dilution of 1:100 in Leica antibody diluent. The staining methodology has been described previously (24). Immunohistochemical detection of ER phosphorylated at serine 118 (P-Ser118) was carried out as detailed before (27). Immunostaining was assessed using the H-scoring method and the X-tile software (28) was used to produce cut-off points for low and high expression levels, as described (24). In brief, this involved random assignment of the patient cohort into two separate training and validation groups ranked by the patient follow-up time. Checking the obtained cut-off points to the validation set tested statistical significance. IHC and scoring for all other proteins has previously been described (29, 30).

Statistical analyses

Statistical analysis of IHC scores for the breast cancer TMAs was performed using SPSS 21 software (SPSS Inc, Chicago, IL, USA). The association between CDK7, CyclinH and

MAT1 and clinicopathological parameters was determined using the Pearson's chi-squared test. Survival curves were estimated by the Kaplan-Meier method with a log-rank test to assess the significance. Multivariate Cox proportional hazard regression models were used to determine independent prognostic effect of variables.

siRNA transfections

MCF-7 cells were transfected with siRNA using the lipofectamine RNAiMAX reverse transfection protocol (Life technologies), as described previously (31). siRNAs for CDK7 (s2829, s2830), CyclinH (s2537 and s2538), MAT1 (s8898 and s8900) and non-targeting (control) siRNA (4390844) were obtained from Life Technologies, UK. Forty-eight hours post-transfection, cells were lysed in RIPA buffer. Immunblotting was carried out using antibodies for CDK7 (ab9516), CyclinH (ab54903) and ß-actin (ab6276), purchased from Abcam (UK), as described previously (31). Antibodies for MAT1 (sc-13598), TBP (sc-421) and P-Ser118 (sc-12915) were purchased from Santa Cruz (USA) and ER (VP-E614) from Vector laboratories. For performing RT-qPCR, MCF-7 cells were transfected with siRNAs for CDK7, CyclinH and MAT1, purchased from Dharmacon, USA. Total RNA was prepared using the RNeasy kit, according to manufacturer's methods (Qiagen).

RESULTS

CDK7, CyclinH and MAT1 are overexpressed in breast cancer

To compare CDK7 expression in normal and malignant breast tissue, we prepared total RNA from 20 breast cancers and matched adjacent normal breast tissue (Fig. 1A-C, Supplementary Fig. 1A-C). CDK7 was detectable in all samples at the mRNA level. Interestingly, the majority of tumours were characterised by higher CDK7 expression, compared with the matched adjacent normal tissue. Mean CDK7 expression was 2.2-fold higher in tumours, compared with the adjacent normal tissue (p=0.006). CyclinH and MAT1 expression was similarly elevated in breast cancer, CyclinH (p=0.0061) and MAT1 (p=0.0057) levels in tumours being 1.9 and 2.1 fold higher respectively, than in the normal breast. EpCAM is an epithelial marker, the expression of which can be elevated in breast cancer (32). EpCAM mRNA levels were not significantly different in our samples (Supplementary Fig. 1D), indicating that the elevated CDK7 expression in this series is unlikely to be due to lower epithelial cellularity of the adjacent normal tissue. IHC of a small series of breast cancer samples showed that nuclear CDK7 immunostaining intensity was consistently higher in tumor cells, compared with CDK7 levels in adjacent normal elements (Supplementary Fig. 1E, F). Cyclin H levels were also elevated in tumor cells compared with adjacent normal elements. However, MAT1 levels were not different between normal and cancer cells.

We next analysed CDK7, CyclinH and MAT1 expression in the METABRIC microarray dataset of 1,556 breast cancers and 144 normal breast samples (33). As observed by qRT-PCR in our samples, CDK7 ($p = 1.49 \times 10^{-38}$), CyclinH ($p = 9.41 \times 10^{-4}$) and MAT1 ($p = 9.06 \times 10^{-10}$) expression was also elevated in breast cancer, compared to expression in normal breast in this data set (Fig. 1D).

Interestingly, these analyses indicated that expression of CDK7, CyclinH and MAT1 may be co-regulated (for example, see patient samples 1, 2, 10 and 11; Supplementary Fig. 1A-C). Pair-wise comparison using Pearson correlation coefficient analysis showed that the expression of CDK7 and CyclinH is indeed strongly associated in this tumour series (r^2=0.861; p<0.0001), as is the expression of CDK7 and MAT1 (r^2=0.879; p<0.0001) and CyclinH and MAT1 (r^2=0.862; p<0.0001) (Supplementary Fig. 2A-C). In agreement with this, Pearson correlation coefficient analysis of the 1,959 samples in the METABRIC cohort showed evidence of a relationship between expression of CDK7 and CyclinH (r^2=0.28), CDK7 and MAT1 (r^2=0.25) and an especially strong association between CyclinH and MAT1 expression (r^2=0.69) (Supplementary Fig. 2D). The difference in strength of associations in our cohort and METABRIC may reflect, at least in part, differences in proportions of different breast cancer subtypes. Indeed, whereas 63% (47/74) of tumors in our cohort are ER-positive, compared with 77% (1489/1928) of the samples in METABRIC. Analysis of TCGA and other breast cancer data sets showed that mutations, amplification and/or deletion of the CDK7, cyclinH and/or MAT1 genes are uncommon (Supplementary Fig. 2E), so their elevated expression and/or co-regulation are unlikely to be the result of gene rearrangement.

To determine if co-regulation of the CDK7, CyclinH and MAT1 genes can be confirmed experimentally in breast cancer cells, we performed siRNA for CDK7 in MCF-7 cells. Efficient CDK7 knockdown was achieved at both the mRNA and protein levels (Fig. 1E, 1H). Additionally, siCDK7 transfection also resulted in CyclinH and MAT1 down-regulation at the mRNA and protein levels (Fig. 1F-H). Similarly, transfection of MCF-7 cells with CyclinH siRNA led to reductions in CyclinH, but also reductions in the levels of CDK7 and MAT1 mRNA and protein. Finally, MAT1 siRNA reduced MAT1, but also CDK7 and CyclinH expression. By contrast, expression of the TFIIH p62 subunit was unaffected, as were TBP and ER levels, suggesting that the siRNA mediated lowered CAK expression is specific. In agreement with our findings, reduction in protein levels of all three CAK subunits have been reported for CDK7 and MAT1 knockout mice (21, 34). What is

striking from our results is that knockdown of one CAK subunit not only results in reduction in protein levels of the other subunits, which might be attributable to disruption of the CAK complex; rather mRNA levels of the other subunits are reduced, implicating transcriptional or post-transcriptional mechanisms in the co-ordinate regulation of CAK subunit mRNA levels. Finally, immunoblotting of MCF7 cells sorted by flow cytometry showed similar expression patterns for CDK7, cyclinH and MAT1 through the cell cycle, with highest levels of each subunit in G1 and G2/M (Supplementary Fig. 3A-B). siRNA mediated knockdown of CDK7 was not associated with cell cycle arrest, but resulted in apoptosis (Supplementary Fig. 3C), as has been described for CDK7 inhibitors BS-181 and THZ1 (17, 18).

CDK7, CyclinH and MAT1 expression is associated with better patient outcome in breast cancer

In order to determine expression of the CAK complex proteins in breast cancer and to analyse associations with clinical features, we carried out IHC of breast cancer TMAs for CDK7 (n=945), CyclinH (n=1218) and MAT1 (n=910) (Fig. 2A). Differential staining was evident for different samples, so the H-scoring method and cut-off H-scores were used to segregate tumours into high and low expression groups. Spearman Rank correlation of protein levels for the CAK subunits (H-scores) showed that expression of CDK7, CyclinH and MAT1 is strongly associated (p<0.001; Fig. 2B), as was observed for mRNA levels, further evidence for an important relationship between expression of the three CAK subunits in breast cancer.

There was a suggestion of an association of CDK7 expression with age in patients aged between 51-60 (p=0.042), but not with menopausal status (p=0.39) (Table 1). High MAT1 levels were also weakly associated with age (p=0.044), but not with menopausal status (p=0.22). Importantly, elevated expression of CDK7, CyclinH and MAT1 was

associated with markers of better prognosis. Hence, patients with high grade and larger tumors, or those who developed recurrent disease, featured low CDK7, CyclinH and/or MAT1 expression. As expected from the association of high levels of the CAK components with low tumor grade and reduced recurrence, high CDK7 expression was associated with longer breast cancer specific survival (BCSS) (log-rank = 4.11, p = 0.04) (Fig. 2C). Multivariate Cox hazard analysis including tumour stage, size, grade and lymph node (LN) status showed an increased significance of CDK7 with longer BCSS (HR=0.65 (0.41-0.84), p=0.001) (Table 2). Multivariate analysis also showed a benefit for high CDK7 expression for time to distant metastasis (TTDM) (Supplementary Table 1). High CyclinH (log-rank = 7.32, p = 0.007) and MAT1 (log-rank = 8.43, p = 0.004) were also associated with longer BCSS. Univariate analysis for low or high expression of all three CAK subunits maintained the survival benefit (log rank = 6.09, p=0.014). In the multivariate analysis model tumour size, LN status and HER2 status, along with BCSS were significantly associated with high CyclinH (p = 0.003) and MAT1 expression (p = 0.016), as was high expression of all three proteins (CAK) (p=0.001) (Table 2, Supplementary Table 1).

Expression levels of the CAK subunits are associated with ER expression in breast cancer

Interestingly, CDK7 (p=0.001), CyclinH (p<0.001) and MAT1 (p<0.001) levels were higher in ER-positive than in ER-negative breast cancer (Table 3) and there was a positive association of CDK7 (p=0.002), CyclinH (p<0.001) and MAT1 (p<0.001) levels with PGR positivity, together indicative of higher CAK levels in luminal breast cancer. This was further confirmed by the fact that CDK7, cyclinH and MAT1 levels were associated with androgen receptor (AR) positivity, as AR expression is strongly associated with ER (35, 36). There was also a significant association with the luminal A marker, GATA3 (37), although there was an inverse relationship with FOXA1, another important marker of

luminal A breast cancer. Indeed, CDK7, CyclinH and MAT1 levels were lower in HER2-positive than in HER2-negative breast cancer and in triple-negative (TN), compared with non-TN breast cancer.

Real-time RT-PCR analysis of RNAs prepared from 74 independent breast cancers showed that CDK7 mRNA levels are also positively associated with ER mRNA levels (r^2 = 0.56, p < 0.0001) (Supplementary Fig. 4A), as are CyclinH (r^2 = 0.46, p < 0.0001) and MAT1 (r^2 = 0.44, p < 0.0001) mRNA levels. As expected, a relationship between ER and PGR mRNA levels (r^2 = 0.63, p < 0.0001) was also observed in this patient series. The association was also evident when comparing CDK7, CyclinH and MAT1 mRNA levels with immunohistochemically defined ER status in this sample set (supplementary Fig. 4B, C). Further confirming this association, CDK7, CyclinH and MAT1 mRNA expression was also positively associated with ER mRNA levels in the METABRIC dataset (Supplementary Fig. 4D). Analysis of the CAK expression in the PAM50 breast cancer subtypes showed slightly higher expression in luminal B than in luminal A breast cancer; p=0.03, 0.02 and <2.2e-16 for CDK7, cyclinH and MAT1, respectively (Supplementary Fig. 4E-G). Moreover, CAK expression was significantly higher in luminal A/B than in HER2+ or in basal breast cancer. Interestingly, expression of each of the CAK subunits was also higher in HER2-positive than in basal breast cancer.

Taken together, the simplest explanation for the high expression of CAK in ER-positive breast cancer is that ER regulates their expression. However, treatment of MCF-7 cells with estrogen did not affect expression of any of the subunits (supplementary Fig. 5A). ER knockdown also did not alter CAK levels (supplementary Fig. 5B) and examination of ER ChIP-seq for MCF-7 cells (38) did not identify ER binding regions within the genes nor within 50 kb 5' or 3' to the CDK7, CyclinH or MAT1 genes, indicating that the association between expression of these genes and ER expression is not due to direct regulation of their expression by ER. Interestingly, high expression of the CAK complex in our TMA

series was associated with longer time to distant metastasis (TTDM) (log rank = 6.68; p=0.01) and BCSS in ER-positive breast cancer (log rank = 5.61; p=0.018) (Fig. 2D-E).

Evidence for a role of CDK7 in phosphorylation of ER at serine 118 in breast cancer

Phosphorylation of ER at serine 118 (Ser118) promotes ER activity and CDK7 has been shown to mediate ligand-dependent phosphorylation of Ser118 (8, 39) and CDK7 knockdown resulted in reduction in Ser118 phosphorylation (Fig. 1H). To determine if Ser118 phosphorylation is related to CDK7 expression in breast cancer, we performed IHC for ER phosphorylated at Ser118 (P-Ser118). In agreement with previous findings linking Ser118 phosphorylation with better prognosis (40), Ser118 phosphorylation was associated with better BCSS and TTDM and BCSS, high P-Ser118 levels being correlated with better survival, patients with intermediate P-Ser118 have worse prognosis and patients with very low/absent P-Ser118 having the poorest survival (TTDM Log rank = 19.9, p<0.001; BCSS Log rank = 13.0, p=0.005) (Supplementary Fig. 3).

More than half (54.1%) of the CDK7-low breast cancers were negative or were weakly positive for P-Ser118, compared with just 26.2% of the CDK7-high tumours (p < 0.001; χ^2 = 56.3) (Table 4). As expected, similarly strong associations were obtained for P-Ser118 and CyclinH (p <0.001; χ^2 = 43.8), and P-Ser118 and MAT1 (p <0.001; χ^2 = 66.5).

DISCUSSION

The importance of CDK7 in cell cycle regulation and transcription has highlighted this kinase as a potential therapeutic target for cancer treatment. In line with this, recently described CDK7 selective inhibitors show anti-tumour activity in several cancer models (17-20). Importantly, these studies show that transcriptional drivers that are especially important in specific cancer types, for example, RUNX1 in leukaemia, are particularly sensitive to CDK7 inhibition (18). Similarly, hypersensitivity of the MYCN (neuroblastoma) (20) and MYC (lung cancer) (19) genes to CDK7 inhibition has been described and appears to be due to hypersensitivity of super-enhancers that drive expression of these factors. Given this diverse range of tumour types that potentially respond, we wanted to determine if CDK7 expression is altered in cancer, as expression and activity may be important factors in the utility of CDK7 inhibitors in the clinic. We chose to investigate CDK7 expression in breast cancer, since we have previously shown that a selective CDK7 inhibitor, BS-181, inhibits breast cancer cell growth *in vitro* and *in vivo* (17). Moreover, CDK7 directly regulates the transcriptional activity of ER by phosphorylating Ser118 (8, 39); thus CDK7 inhibitors might be especially effective in ER-positive breast cancer featuring elevated Ser118 phosphorylation.

Comparison of breast cancers with matched adjacent normal tissue showed that CDK7 mRNA levels are elevated in this tumour type. This was confirmed by analysis of microarray datasets and is in agreement with previous reports which suggested that CDK7 protein levels are higher in cancer compared to the normal breast (41, 42). It is possible that these observations reflect differences in epithelial cell content. However, real-time RT-PCR for EpCAM, as well as comparison of CDK7 IHC for normal breast with CDK7 levels in tumor samples indicates that CDK7 levels are indeed elevated in breast cancer. Mutations and gene rearrangements at the CAK gene loci are uncommon, so this is unlikely to represent a major mechanism for high expression in breast cancer. Interestingly, the CDK7 and CyclinH genes are located 18 Mb apart on human

chromosome 5 and, are also linked in the genomes of several other vertebrates, including Zebrafish, chicken, rodents and man, making co-regulation through common gene regulatory elements possible.

Remarkably, we observed that mRNA and protein levels of CyclinH and MAT1, both of which are required for CDK7 activity, are also increased in breast cancer, indicative of up-regulation of CAK activity in breast cancer. siRNA experiments also showed that knockdown of any one CAK subunit resulted in reduced expression of the other subunits, implying co-regulation of the expression of the CAK complex at the transcriptional level. Whilst the exact mechanisms underlying this co-regulation remain unclear, treatment with the CDK7 inhibitor BS-181 resulted in reduced CDK7 protein levels (17) and THZ1, a covalent CDK7 inhibitor inhibits PolII recruitment to gene promoters (18), indicating that expression of the CAK complex is strongly linked to CDK7 activity. It is possible that this co-regulation is due to loss of CAK subunits in apoptotic cells. Notwithstanding, IHC staining of >900 breast cancers also demonstrated a significant association between levels of CDK7, CyclinH and MAT1, which together with the association for mRNA expression of the CAK subunits, provides strong evidence for co-regulation of CAK subunit expression in breast cancer.

Interestingly, high-level expression of each of the CAK subunits was associated with longer survival in univariate and multivariate analyses. The relationship between CDK7 and prognosis in breast cancer seems analogous to the relationship between ER and prognosis, in that ER confers a good prognosis, but is at the same time a suitable target for therapy. Moreover, the majority of tumours with high CDK7 levels were ER-positive, as were tumours with high levels of CyclinH and MAT1. In agreement with this, real-time RT-PCR and analysis of the METABRIC microarray datasets showed positive associations between mRNA levels of each CAK subunit with ER mRNA levels, as well as ER status. In ER-positive breast cancer, CAK expression was also associated with better prognosis. This does not appear to be due to higher CAK expression in luminal A compared to

luminal B breast cancer. Indeed, in METABRIC, CAK transcript levels are similar to, or higher in luminal B than in luminal A breast cancer. The mechanisms underlying the association between CDK7, CyclinH and MAT1 expression and ER are unclear, but it is interesting to note that CAK levels were strongly associated with ER phosphorylation at Ser118, which provides *in vivo* evidence for the previously described role of CDK7 in phosphorylating this residue (8). Ser118 phosphorylation is important not only for stimulating ER activity, but also regulates ER degradation and consequently ER levels (43, 44). This might afford a potential explanation for the relationship between levels of CAK and ER protein in breast cancer. Moreover, ER positively regulates its own gene expression, at least in part through a positive cross-regulatory loop with GATA-3 mRNA levels (45). CDK7 may thus promote ER gene expression by promoting its activity through phosphorylation of Ser118. Alternatively, transcription of the ER gene may be particularly sensitive to CDK7 activity, as demonstrated by the sensitivity of the RUNX1 and MYC genes in other cancers (18).

We previously reported the first specific, small molecule CDK7 inhibitor, BS-181 (17). We showed that BS181 promotes p53-dependent and independent apoptosis, at least in part by inhibiting the expression of short-lived transcripts for genes encoding inhibitors of apoptosis. The additional work presented here shows that CAK siRNA reduces ER phosphorylation, in line with its known action on ER phosphorylation at Ser118 (8). Our findings, therefore, offer some explanation as to why CDK7 expression carries a good prognosis in patients with ER positive breast cancer, in that in our sets, these patients have been treated with adjuvant endocrine therapy, where improved survival, is dependent on a functioning ER, for which Ser118 phosphorylation is critical.

In summary, CDK7, CyclinH and MAT1 mRNA and protein levels are elevated in breast cancer, particularly in ER-positive breast cancer. Given the important role of CDK7 in regulation of transcription, as well as its role in the direct regulation of ER activity through phosphorylation of Ser118, our findings support the potential use of CDK7

inhibitors in the treatment of ER-positive breast cancer, either as a single agent, or in combination with hormonal therapy, with perhaps the most suitable group for treatment being ER-positive breast cancer patients with high CDK7 and P-Ser118 levels.

Author Contributions: S.A. H.P., R.A., R.C.C., F.F-P., S.S., L.B., E.A.R., I.O.E. conceived all experiments. H.P., R.A. and J.R. performed the experiments, with help from the other authors. B.G, L. M. and C. G. performed the analyses of microarray data. H.P. and S.A. wrote the manuscript with advice from all authors.

Author Information: Correspondence should be addressed to S.A. (simak.ali@imperial.ac.uk).

Figure legends

Fig. 1. CDK7, CyclinH and MAT1 mRNA levels are elevated in breast cancer and show evidence of coordinate regulation. (A-C) CDK7, CyclinH and MAT1 mRNA levels, determined by real-time RT-PCR analysis, were normalised to the expression of GAPDH for RNA prepared from 20 paired tumour and adjacent normal tissues. **(D)** Analysis of microarray data from the METABRIC samples for expression of CDK7, CyclinH and MAT1 in normal breast and breast cancer samples. **(E-G)** MCF-7 cells were transfected with two independent siRNAs for CDK7, CyclinH and MAT1. Real-time RT-PCR was performed using RNA prepared 48 hours after transfection. CDK7, CyclinH and MAT1 expression is shown relative to expression of GAPDH for three independent samples. Expression of all three genes was significantly reduced (p<0.001) for each siRNA when compared with the control siRNA. **(H)** Immunoblotting was performed using protein lysates prepared following siRNA transfection as above.

Fig. 2. Immunohistochemical analysis of CDK7, CyclinH and MAT1 expression in breast cancer. CDK7, CyclinH and MAT1 antibodies were used to immunostain breast cancer TMAs. The sections were scored as CDK7 low (H-score: 0-160), CDK7 high (H-score: 161-300), CyclinH low (H-score: 0-194), CyclinH high (H-score: 195-300), MAT1 low (H-score: 0-179) or MAT1 high (H-score: 180-300). Negative controls were performed by omitting the primary antibody. **(A)** Staining representative of low and high H-scores is shown. **(B)** Pearson's correlation analysis is shown, together with r^2 values for each pair-wise comparison. **(C)** Kaplan-Meier plots showing breast cancer specific survival (BCSS) for CDK7, CyclinH and MAT1 expression in breast cancer. (D) COX regression analysis for time to distant metastasis (TTDM) and breast cancer specific survival (BCSS) for ER-positive breast cancer samples only. **(E)** KM Plot of high versus low CAK levels in ER-positive breast cancer.

References

1.   Malumbres M, Barbacid M. Mammalian cyclin-dependent kinases. Trends in biochemical sciences. 2005;30:630-41.

2.   Fisher RP. Secrets of a double agent: CDK7 in cell-cycle control and transcription. Journal of cell science. 2005;118:5171-80.

3.   Lu H, Fisher RP, Bailey P, Levine AJ. The CDK7-cycH-p36 complex of transcription factor IIH phosphorylates p53, enhancing its sequence-specific DNA binding activity in vitro. Molecular and cellular biology. 1997;17:5923-34.

4.   Rochette-Egly C, Adam S, Rossignol M, Egly JM, Chambon P. Stimulation of RAR alpha activation function AF-1 through binding to the general transcription factor TFIIH and phosphorylation by CDK7. Cell. 1997;90:97-107.

5.   Bastien J, Adam-Stitah S, Riedl T, Egly JM, Chambon P, Rochette-Egly C. TFIIH interacts with the retinoic acid receptor gamma and phosphorylates its AF-1-activating domain through cdk7. The Journal of biological chemistry. 2000;275:21896-904.

6.   Lee DK, Duan HO, Chang C. From androgen receptor to the general transcription factor TFIIH. Identification of cdk activating kinase (CAK) as an androgen receptor NH(2)-terminal associated coactivator. The Journal of biological chemistry. 2000;275:9308-13.

7.   Chymkowitch P, Le May N, Charneau P, Compe E, Egly JM. The phosphorylation of the androgen receptor by TFIIH directs the ubiquitin/proteasome process. The EMBO journal. 2011;30:468-79.

8.   Chen D, Riedl T, Washbrook E, Pace PE, Coombes RC, Egly JM, et al. Activation of estrogen receptor alpha by S118 phosphorylation involves a ligand-dependent interaction with TFIIH and participation of CDK7. Molecular cell. 2000;6:127-37.

9.   Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nature reviews Cancer. 2001;1:222-31.

10.   Lolli G, Johnson LN. CAK-Cyclin-dependent Activating Kinase: a key kinase in cell cycle control and a target for drugs? Cell cycle. 2005;4:572-7.

11.   Peyressatre M, Prevel C, Pellerano M, Morris MC. Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors. Cancers (Basel). 2015;7:179-237.

12.   Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nature reviews Cancer. 2009;9:153-66.

13.   Merrick KA, Fisher RP. Why minimal is not optimal: driving the mammalian cell cycle--and drug discovery--with a physiologic CDK control network. Cell cycle. 2012;11:2600-5.

14.   DeMichele A, Clark AS, Tan KS, Heitjan DF, Gramlich K, Gallagher M, et al. CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015;21:995-1001.

15.   Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006;24:1770-83.

16.   Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. The lancet oncology. 2015;16:25-35.

17.   Ali S, Heathcote DA, Kroll SH, Jogalekar AS, Scheiper B, Patel H, et al. The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity. Cancer research. 2009;69:6208-15.

18.   Kwiatkowski N, Zhang T, Rahl PB, Abraham BJ, Reddy J, Ficarro SB, et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature. 2014;511:616-20.

19.   Christensen CL, Kwiatkowski N, Abraham BJ, Carretero J, Al-Shahrour F, Zhang T, et al. Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor. Cancer cell. 2014;26:909-22.

20.   Chipumuro E, Marco E, Christensen CL, Kwiatkowski N, Zhang T, Hatheway CM, et al. CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer. Cell. 2014;159:1126-39.

21.   Ganuza M, Saiz-Ladera C, Canamero M, Gomez G, Schneider R, Blasco MA, et al. Genetic inactivation of Cdk7 leads to cell cycle arrest and induces premature aging due to adult stem cell exhaustion. Embo Journal. 2012;31:2498-510.

22.   Purdie CA, Baker L, Ashfield A, Chatterjee S, Jordan LB, Quinlan P, et al. Increased mortality in HER2 positive, oestrogen receptor positive invasive breast cancer: a population-based study. British journal of cancer. 2010;103:475-81.

23.   Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JF, et al. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. International journal of cancer Journal international du cancer. 2005;116:340-50.

24.   Jerjees DA, Alabdullah M, Green AR, Alshareeda A, Macmillan RD, Ellis IO, et al. Prognostic and biological significance of proliferation and HER2 expression in the luminal class of breast cancer. Breast cancer research and treatment. 2014;145:317-30.

25.   Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(T)(-Delta Delta C) method. Methods. 2001;25:402-8.

26.   Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Barrette TR, Ghosh D, Chinnaiyan AM. Mining for regulatory programs in the cancer transcriptome. Nature genetics. 2005;37:579-83.

27.   Sarwar N, Kim JS, Jiang J, Peston D, Sinnett HD, Madden P, et al. Phosphorylation of ERalpha at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERalpha phosphorylation in breast cancer progression. Endocrine-related cancer. 2006;13:851-61.

28.   Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clinical cancer

research : an official journal of the American Association for Cancer Research. 2004;10:7252-9.

29.	Abduljabbar R, Negm OH, Lai CF, Jerjees DA, Al-Kaabi M, Hamed MR, et al. Clinical and biological significance of glucocorticoid receptor (GR) expression in breast cancer. Breast cancer research and treatment. 2015;150:335-46.

30.	Habashy HO, Powe DG, Rakha EA, Ball G, Paish C, Gee J, et al. Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance. European journal of cancer. 2008;44:1541-51.

31.	Lai CF, Flach KD, Alexi X, Fox SP, Ottaviani S, Thiruchelvam PT, et al. Co-regulated gene expression by oestrogen receptor alpha and liver receptor homolog-1 is a feature of the oestrogen response in breast cancer cells. Nucleic acids research. 2013.

32.	Gastl G, Spizzo G, Obrist P, Dunser M, Mikuz G. Ep-CAM overexpression in breast cancer as a predictor of survival. Lancet. 2000;356:1981-2.

33.	Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486:346-52.

34.	Sano M, Izumi Y, Helenius K, Asakura M, Rossi DJ, Xie M, et al. Menage-a-trois 1 is critical for the transcriptional function of PPARgamma coactivator 1. Cell metabolism. 2007;5:129-42.

35.	Lin ML, Patel H, Remenyi J, Banerji CR, Lai CF, Periyasamy M, et al. Expression profiling of nuclear receptors in breast cancer identifies TLX as a mediator of growth and invasion in triple-negative breast cancer. Oncotarget. 2015;6:21685-703.

36.	Peters AA, Buchanan G, Ricciardelli C, Bianco-Miotto T, Centenera MM, Harris JM, et al. Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res. 2009;69:6131-40.

37.	Lacroix M, Leclercq G. About GATA3, HNF3A, and XBP1, three genes co-expressed with the oestrogen receptor-alpha gene (ESR1) in breast cancer. Molecular and cellular endocrinology. 2004;219:1-7.

38.   Ross-Innes CS, Stark R, Teschendorff AE, Holmes KA, Ali HR, Dunning MJ, et al. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature. 2012;481:389-93.

39.   Chen D, Washbrook E, Sarwar N, Bates GJ, Pace PE, Thirunuvakkarasu V, et al. Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera. Oncogene. 2002;21:4921-31.

40.   Murphy LC, Seekallu SV, Watson PH. Clinical significance of estrogen receptor phosphorylation. Endocrine-related cancer. 2011;18:R1-14.

41.   Bartkova J, Zemanova M, Bartek J. Expression of CDK7/CAK in normal and tumor cells of diverse histogenesis, cell-cycle position and differentiation. International journal of cancer Journal international du cancer. 1996;66:732-7.

42.   Zhang J, Yang X, Wang Y, Shi H, Guan C, Yao L, et al. Low expression of cyclinH and cyclin-dependent kinase 7 can decrease the proliferation of human esophageal squamous cell carcinoma. Digestive diseases and sciences. 2013;58:2028-37.

43.   Rajbhandari P, Schalper KA, Solodin NM, Ellison-Zelski SJ, Ping Lu K, Rimm DL, et al. Pin1 modulates ERalpha levels in breast cancer through inhibition of phosphorylation-dependent ubiquitination and degradation. Oncogene. 2014;33:1438-47.

44.   Valley CC, Metivier R, Solodin NM, Fowler AM, Mashek MT, Hill L, et al. Differential regulation of estrogen-inducible proteolysis and transcription by the estrogen receptor alpha N terminus. Molecular and cellular biology. 2005;25:5417-28.

45.   Eeckhoute J, Keeton EK, Lupien M, Krum SA, Carroll JS, Brown M. Positive cross-regulatory loop ties GATA-3 to estrogen receptor alpha expression in breast cancer. Cancer research. 2007;67:6477-83.

Table 1. CDK7, CycH and MAT1 expression and clinic-pathological associations

Variable	CDK7 Expression (%)			CycH Expression (%)			MAT1 Expression (%)		
	Low (0-160)	High (161-300)	p-value	Low (0-194)	High (195-300)	p-value	Low (0-179)	High (180-300)	p-value
Age									
<40	16 (5.9)	65 (9.7)		59 (9.7)	46 (7.6)		38 (8.6)	40 (8.7)	
41-50	72 (26.8)	172 (25.6)	0.042	159 (26.2)	167 (27.6)	0.34	111 (25.2)	130 (28.1)	0.044
51-60	*100 (37.2)*	*198 (29.5)*		198 (32.6)	182 (30)		*158 (35.8)*	*126 (27.3)*	
>60	81 (30.1)	236 (30.1)		192 (31.6)	211 (34.8)		*134 (30.4)*	*166 (35.9)*	
Menopausal Status									
Pre-	100 (37.6)	259 (38.9)	0.39	237 (39.4)	238 (39.5)	0.97	162 (37.1)	189 (41.1)	0.22
Post-	166 (62.4)	407 (61.1)		365 (60.6)	365 (60.5)		275 (62.9)	271 (58.9)	
Tumour Size (cm)									
< 2.0	121 (44.8)	326 (48.9)	0.28	273 (45)	307 (50.6)	0.051	*185 (42)*	*246 (53.7)*	<0.001
≥ 2.0	149 (55.2)	341 (51.1)		334 (55)	300 (49.4)		*255 (58)*	*212 (46.3)*	
Grade									
1	36 (13.4)	98 (14.7)		*84 (13.9)*	*109 (18)*		*53 (12.1)*	*85 (18.6)*	
2	82 (30.5)	239 (35.9)	0.16	*174 (28.7)*	*229 (37.9)*	<0.001	*118 (26.9)*	*176 (38.4)*	<0.001
3	151 (56.1)	328 (49.3)		*348 (57.4)*	*266 (44)*		*268 (61)*	*197 (43)*	
Lymph Node									
Negative	*186 (68.9)*	*382 (57.2)*	0.001	382 (62.9)	363 (59.8)	0.26	*286 (65)*	*264 (57.5)*	0.021
Positive	*84 (31.1)*	*286 (42.8)*		225 (37.1)	244 (40.2)		*154 (35)*	*195 (42.5)*	
Local Recurrence									
No	210 (79.2)	555 (84.3)	0.07	501 (84.1)	486 (82.5)	0.48	355 (81.8)	376 (83.2)	0.59
Yes	55 (20.8)	103 (15.7)		95 (15.9)	103 (17.5)		79 (18.2)	76 (16.8)	
Regional Recurrence									
No	*212 (80)*	*576 (77.5)*	0.003	510 (85.6)	516 (87.6)	0.3	*351 (80.9)*	*399 (88.3)*	0.002
Yes	*53 (20)*	*82 (22.5)*		86 (14.4)	73 (12.4)		*83 (19.1)*	*53 (11.7)*	
Distant Metastasis									
No	*149 (55.2)*	*417 (62.4)*	0.04	373 (61.6)	388 (64.1)	0.35	*251 (56.9)*	*304 (65.9)*	0.005
Yes	*121 (44.8)*	*251 (37.6)*		233 (38.4)	217 (35.9)		*190 (43.1)*	*157 (34.1)*	

Table 2. Multivariate Cox Regression Analysis for Breast Cancer Specific Survival (BCSS)

Variable	P-value	HR	95% CI	
Tumour size	0.002	1.48	1.15	1.90
Stage	<0.001	1.97	1.65	2.35
Grade	<0.001	1.78	1.45	2.19
HER2	<0.001	1.69	1.26	2.26
CDK7	0.001	0.65	0.51	0.84

Variable	P-value	HR	95% CI	
Tumour size	0.001	1.49	1.18	1.88
Stage	<0.001	1.91	1.65	2.23
Grade	<0.001	1.85	1.54	2.23
HER2	<0.001	1.67	1.28	2.20
CycH	0.003	0.72	0.58	0.90

Variable	P-value	HR	95% CI	
Tumour size	0.049	1.28	1.01	1.63
Stage	<0.001	1.82	1.53	2.16
Grade	0.001	1.38	1.15	1.66
HER2	0.001	1.66	1.24	2.23
MAT1	0.016	0.75	0.59	095

Variable	P-value	HR	95% CI	
Tumour size	0.002	1.82	1.25	2.65
Stage	<0.001	1.95	1.50	2.53
Grade	0.10	1.29	0.95	1.76
HER2	0.002	2.09	1.32	3.32
CAK	0.001	0.53	0.37	0.78

Table 3. Relationship between CDK7, Cyclin H and MAT1 expression and breast cancer subtypes

Variable	CDK7			Cyclin H			MAT1		
	Low (0-160)	High (161-300)	p-value (χ^2)	Low (0-194)	High (195-300)	p-value (χ^2)	Low (0-179)	High (180-300)	p-value (χ^2)
ER									
Negative	87 (32.2)	148 (22.2)	0.001	194 (32.1)	117 (19.4)	<0.001	151 (34.2)	93 (20.3)	<0.001
Positive	183 (67.8)	520 (77.8)	(10.4)	410 (67.9)	486 (80.6)	(25.5)	291 (65.8)	365 (79.7)	(21.9)
PGR									
Negative	128 (49.2)	248 (38.3)	0.002	292 (49.6)	191 (33)	<0.001	214 (49.7)	157 (35.7)	<0.001
Positive	132 (50.8)	400 (61.7)	(9.2)	297 (50.4)	388 (67)	(33.1)	217 (50.3)	283 (64.3)	(17.4)
ER/PGR Status									
ER+/PGR+	132 (50.8)	400 (61.7)	0.003	295 (50.3)	387 (67.1)	<0.001	217 (50.3)	282 (64.4)	<0.001
ER+/PGR-	46 (17.7)	108 (16.7)	(11.4)	104 (17.7)	80 (13.9)	(35.4)	68 (15.8)	71 (16.2)	(25.6)
ER-/PGR-	82 (31.5)	140 (21.6)		187 (31.9)	110 (19.1)		146 (33.9)	85 (19.4)	
AR									
Negative	125 (52.7)	199 (33.2)	<0.001	249 (46.5)	155 (28.9)	<0.001	179 (46.9)	120 (29.3)	<0.001
Positive	112 (47.3)	400 (66.8)	(27.3)	287 (53.5)	381 (71.1)	(35.1)	203 (53.1)	290 (70.7)	(26.0)
FOXA1									
Negative	67 (34.7)	209 (48.5)	0.001	154 (37.6)	199 (52.5)	<0.001	119 (36.1)	150 (52.8)	<0.001
Positive (≥10)	126 (65.3)	222 (51.5)	(10.3)	256 (62.4)	180 (47.5)	(17.8)	211 (63.9)	134 (47.2)	(17.4)
GATA3									
Negative/Low (<60)	154 (87.5)	277 (71.9)	<0.001	310 (83.8)	229 (70.2)	<0.001	245 (86)	177 (67.3)	<0.001
Positive (≥60)	22 (12.5)	108 (28.1)	(16.4)	60 (16.2)	97 (29.8)	(18.2)	40 (14)	86 (32.7)	(26.9)
HER2									
Negative	212 (81.2)	566 (87.5)	0.015	506 (86.3)	500 (86.8)	NS	350 (81.4)	394 (90)	<0.001
Positive	49 (18.8)	81 (12.5)	(5.9)	80 (13.7)	76 (13.2)		80 (18.6)	44 (10)	(13.0)
Triple negative (TN)									
Non-TN	207 (87.7)	554 (84.6)	0.033	453 (76.3)	523 (88.5)	<0.001	329 (76.3)	390 (87.1)	<0.001
TN	56 (21.3)	101 (15.4)	(4.6)	141 (23.7)	68 (11.5)	(30.5)	102 (23.7)	58 (12.9)	(16.9)

Table 4. Phosphorylation levels of ER Serine 118 are associated with CDK7, CycH and MAT1 levels

Variable	P-Ser118-ER				
	Negative (0-50)	Low (51-100)	Moderate (101-200)	High (201-300)	p-value (χ^2)
CDK7					
Low (0-160)	64 (43.8)	15 (10.3)	51 (34.9)	16 (11.0)	<0.001
High (161-300)	63 (15.3)	45 (10.9)	182 (44.1)	123 (29.8)	(56.3)
CycH					
Low (0-194)	81 (36.0)	31 (13.8)	74 (32.9)	39 (17.3)	<0.001
High (195-300)	68 (15.3)	47 (10.6)	197 (44.4)	132 (29.7)	(43.8)
MAT1					
Low (0-179)	84 (35.7)	30 (12.8)	97 (14.3)	24 (10.2)	<0.001
High (180-300)	38 (13.6)	27 (9.6)	109 (38.6)	106 (37.9)	(66.5)

Figure 1

A

	Control	Low	High
CDK7			
CycH			
MAT1			

B

	CDK7	Cyclin H	MAT1
CDK7	1	0.57	0.68
CycH		1	0.53
MAT1			1

C

High CDK7 (n = 216)
Low CDK7 (n = 509)
Log rank = 4.11; p = 0.043

High CycH (n = 457)
Low CycH (n = 465)
Log rank = 7.32; p = 0.007

High MAT1(n = 340)
Low MAT1 (n = 359)
Log rank = 8.43; p = 0.004

High CAK (n = 100)
Low CAK (n = 184)
Log rank = 6.09; p = 0.014

BCSS in months

D

Variable	TTDM			
	P-value	HR	95% CI	
Tumour size	0.007	1.81	1.18	2.79
Stage	0.021	1.43	1.06	1.93
Grade	0.157	1.25	0.92	1.71
HER2	0.002	2.63	1.44	4.80
CDK7	0.047	0.65	0.43	0.99

Variable	BCSS			
	P-value	HR	95% CI	
Tumour size	0.002	2.14	1.31	3.49
Stage	<0.001	1.88	1.35	2.61
Grade	0.03	1.50	1.03	2.18
HER2	0.025	2.11	1.10	4.05
CAK	0.016	0.55	0.33	0.89

E

High CAK (n=61)
Low CAK (n=146)
ER-positive breast cancer
Log rank = 5.61; p = 0.018
BCSS (Months)

Figure 2